Adaptive Biotechnologies beats estimates with Q3 revenue of $26.1M as shares rise 6% Adaptive Biotechnologies‘ stock rose 6 percent to $30 per share in after-hours trading on Tuesday after the company reported higher… Read More
Adaptive Biotechnologies signs blockbuster deal with Genentech for personalized cancer treatments worth up to $2 billion Adaptive Biotechnologies has signed a $300 million collaborative licensing agreement with Genentech to develop highly personalized cancer therapies. In addition… Read More
